← All trials
NCT05000216
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 13, 2021
- Primary completion
- Jan 31, 2022
- Completion date
- Dec 31, 2022
- First posted
- Aug 11, 2021
- Last posted
- Oct 29, 2021
- Enrollment
- 600
- Arms / groups
- 15 / —
- Source
- AACT · ingestion pipeline
Sponsors
- National Institute of Allergy and Infectious Diseases (NIAID)Lead sponsor
- University of MichiganStudy chair
- National Institute of Allergy and Infectious Diseases (NIAID)Collaborator
- Rho, Inc.Collaborator
- Oklahoma Medical Research FoundationStudy chair
- University of PennsylvaniaStudy chair
- Northwell HealthStudy chair
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.